Karolinska insititute
Stockholm, Sweden
NCT Number: NCT01809990
The main goal of this trial is to study the feasibility and effectiveness of internet-delivered cognitive behavior therapy for adolescents with obsessive-compulsive disorder.
Looking for future studies?
Notify Me12 year–17 year
All sexes
Interventional
Not applicable
Stockholm, Sweden
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline, 12 weeks after treatment starts, 3 and 6 months after treatment has ended
Change from Baseline of obsessions and compulsions after 12 weeks and at 3- and 6 months after treatment.
Time frame: Baseline, 12 weeks after treatment starts, 3 and 6 months after treatment has ended
Spence Child Anxiety Scale - Child and Parent version (SCAS/P, Spence, 1998) will be used as a child and parent self-report measure of anxiety related psychopathology.
Time frame: Baseline, 12 weeks after treatment starts, 3 and 6 months after treatment has ended
Symptom severity of depression in the adolescent will be assessed with Child Depression Inventory (CDI, Kovacs, 1985).
Time frame: Baseline, 12 weeks after treatment starts, 3 and 6 months after treatment has ended
Strengths Difficulties Questionnaire (SDQ, Goodman, 1997) is a widely used self- and parent-report behavioral screening questionnaire with six subscales: emotional problems, conduct problems, hyperactivity-inattention, peer problems, prosocial behavior
Time frame: Baseline, 12 weeks after treatment starts, 3 and 6 months after treatment has ended
The Children's Obsessional Compulsive Inventory Revised, (CHOCI-R, Shafran et al., 2003) is a self- and parent-report measure of pediatric OCD symptom severity.
Time frame: Baseline, 12 weeks after treatment starts, 3 and 6 months after treatment has ended
Child Obsessive-Compulsive Impact Scale - Revised (COIS-R, Piacentini, Peris, Bergman, Chang, & Jaffer, 2007) is a self- and parent-report scale of OCD symptom impact on everyday life.
Time frame: Baseline, 12 weeks after treatment starts, 3 and 6 months after treatment has ended
Patient Health Questionnaire PHQ-9 (Kroenke, Spitzer, & Williams, 2001) is a brief self-report measure of depressive symptoms in adults. PHQ-9 will be used to measure parental depressive symptoms.
Time frame: Baseline, 12 weeks after treatment starts, 3 and 6 months after treatment has ended
GAD-7 (Spitzer, Kroenke, Williams, & Löwe, 2006) is a brief self-report measure of symptoms of general anxiety in adults. GAD-7 will be used to measure symptoms of anxiety in the parents.
Time frame: Baseline, 12 weeks after treatment starts, 3 and 6 months after treatment has ended
Obsessive Compulsive Inventory - Revised (OCI-R, Foa et al., 2002) is a reliable and valid 18-item self-report scale for screening of OCD in adults and will be used to measure parental OC symptoms of both parents.
Time frame: Baseline, 12 weeks after treatment starts, 3 and 6 months after treatment has ended
Family Accommodation Scale, Parent-Report (FAS-PR, Flessner et al., 2009). The parent-report version of the FAS consists of 12 items focusing on accommodation behaviors of parents with a child with OCD.
Eva Serlachius
Other
Internet-delivered Cognitive Behavior Therapy for Adolescents With Obsessive-Compulsive Disorder - a Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05552014
Anxiety Disorders, Mental Disorders
Hefei, Anhui, China
View Trial DetailsNCT04967560
Anxiety Disorders, Mental Disorders
Zhengzhou, Henan, China
View Trial DetailsNCT05503017
Anxiety Disorders, Generalized Anxiety Disorder
Tallahassee, Florida, United States
View Trial DetailsNCT04693351
Anxiety Disorders, Mental Disorders
Phoenix, Arizona, United States
View Trial Details